Comparative effectiveness of infliximab and adalimumab for crohn's disease

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 5, 2014, Pages 811-817.e3

  Osterman, Mark T ^a   Haynes, Kevin ^b   Delzell, Elizabeth ^c   Zhang, Jie ^c   Bewtra, Meenakshi ^a,b   Brensinger, Colleen ^b   Chen, Lang ^d   Xie, Fenlong ^d   Curtis, Jeffrey R ^b,c   Lewis, James D ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Hospitalization; Persistence; Surgery; Tumor Necrosis Factor

Indexed keywords

ADALIMUMAB; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABSCESS; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HOSPITALIZATION; HUMAN; INTESTINE PERFORATION; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; STOMA; UNITED STATES; COMPARATIVE STUDY; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADALIMUMAB; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84899099903     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.06.010     Document Type: Article

References (24)

1. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. NEngl J Med 2007, 357:228-238.
2. Kozuch P.L., Hanauer S.B., Kozuch P.L., et al. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008, 14:354-377.
3. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis [erratum appears in N Engl J Med 2006;354:2200]. NEngl J Med 2005, 353:2462-2476.
4. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
5. Van Assche G., Vermeire S., Ballet V., et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012, 61:229-234.
6. Song F., Altman D.G., Glenny A.M., et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472.
7. Available at:. Accessed April2013. http://www.medicare.gov.
8. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. NEngl J Med 2010, 362:1383-1395.
9. Mamdani M., Sykora K., Li P., et al. Reader's guide to critical appraisal of cohort studies: 2-assessing potential for confounding. BMJ 2005, 330:960-962.
10. Hyrich K.L., Lunt M., Watson K.D., et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007, 56:13-20.
11. Zink A., Listing J., Kary S., et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005, 64:1274-1279.
12. Tang B., Rahman M., Waters H.C., et al. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008, 30:1375-1384.
13. Markenson J.A., Gibofsky A., Palmer W.R., et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. JRheumatol 2011, 38:1273-1281.
14. Greenberg J.D., Reed G., Decktor D., et al. Acomparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012, 71:1134-1142.
15. Du Pan S.M., Dehler S., Ciurea A., et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009, 61:560-568.
16. Hetland M.L., Christensen I.J., Tarp U., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32.
17. Blum M.A., Koo D., Doshi J.A. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 2011, 33:901-913.
18. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
19. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease. Gastroenterology 2007, 132:52-65.
20. Grijalva C.G., Chen L., Delzell E., et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306:2331-2339.
21. Hommes D., Colombel J.F., Emery P., et al. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. JCrohns Colitis 2012, 6(Suppl 2):S224-S234.
22. Hanauer S.B., Kirsner J.B. Treat the patient or treat the disease?. Dig Dis 2012, 30:400-403.
23. Sussman D.A., Kubiliun N., Mulani P.M., et al. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis 2012, 18:2043-2055.
24. Health Care Financing Administration. Data user reference guide (DURG) 2000, Health Care Financing Administration, Baltimore, MD.